ST. LOUIS, Mo., June 30, 2026
Aurenar has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its investigational V-Link™ System, a non-invasive neuromodulation therapy designed to reduce cerebral vasospasm in adult patients with aneurysmal subarachnoid hemorrhage (aSAH). The designation marks a significant regulatory milestone for the company’s innovative transauricular vagus nerve stimulation (taVNS) platform, recognizing its potential to address one of the most serious complications following brain hemorrhage. Intended for use as an adjunct to standard clinical management in intensive care units, the wireless V-Link System delivers low-energy electrical stimulation through the outer ear to activate the vagus nerve and regulate inflammatory responses associated with secondary brain injury. Through the FDA’s Breakthrough Devices Program, Aurenar will receive enhanced regulatory interaction and prioritized review as it advances the technology toward pivotal clinical studies and future regulatory submission, accelerating the development of a therapy that could improve survival and neurological outcomes for critically ill stroke patients.
FDA Breakthrough Designation Accelerates Innovative Stroke Therapy
The FDA Breakthrough Device Designation is awarded to medical technologies that demonstrate the potential to provide more effective treatment for life-threatening or irreversibly debilitating diseases. For Aurenar’s V-Link™ System, the designation applies specifically to adults aged 22 years and older with aneurysmal subarachnoid hemorrhage, where the device is intended to reduce the incidence of cerebral vasospasm during intensive care treatment. Cerebral vasospasm occurs when blood vessels constrict following a ruptured brain aneurysm, restricting blood flow to the brain and significantly increasing the risk of stroke, disability, and death.
Despite advances in neurocritical care, there are currently no FDA-approved medical devices specifically designed to prevent cerebral vasospasm, highlighting the importance of this investigational technology. The FDA designation acknowledges both the unmet clinical need and the promising scientific evidence supporting Aurenar’s novel approach to neuromodulation in critical care.
Clinical Research Demonstrates Promising Neurological Outcomes
Advertisement
The scientific foundation behind the V-Link™ System is based on transauricular vagus nerve stimulation, a technology developed through research conducted by Dr. Eric Leuthardt and Dr. Anna Huguenard at Washington University School of Medicine in St. Louis. In a randomized clinical trial involving 27 patients with aneurysmal subarachnoid hemorrhage, the therapy demonstrated a greater than 40% reduction in moderate-to-severe cerebral vasospasm compared with standard care while showing no treatment-related adverse events.
Investigators also reported improved patient outcomes alongside an approximately 20% reduction in 30-day hospitalization costs, suggesting the technology may improve both clinical effectiveness and healthcare efficiency. By targeting inflammatory pathways through controlled vagus nerve stimulation, the V-Link™ System introduces a novel therapeutic strategy aimed at reducing secondary brain injury while remaining simple enough for routine use by physicians and nursing staff within intensive care settings.
Neuromodulation Platform Expands Future Critical Care Innovation
With the Breakthrough Device Designation now secured, Aurenar plans to accelerate the clinical development and commercialization of the V-Link™ System while exploring additional applications for its non-invasive neuromodulation platform across other high-acuity critical care conditions. The company’s wireless, single-use technology has been designed to integrate seamlessly into existing ICU workflows while reducing treatment complexity for healthcare providers. As interest in bioelectronic medicine and neuromodulation therapies continues to grow, innovative platforms capable of regulating the body’s inflammatory response are emerging as promising alternatives to traditional pharmacological interventions.
The FDA’s recognition of the V-Link™ System reinforces the growing role of non-invasive neurostimulation technologies in advancing stroke care and highlights Aurenar’s commitment to developing transformative medical devices that improve patient outcomes while addressing significant unmet clinical needs in neurocritical care.
Source: Aurenar press release
